The Robarts Research Institute has spun off a company that designs and develops clinical imaging platforms for use by biotechnology and pharmaceutical firms. Biomark Imaging Inc will develop platforms to test new therapies for a range of diseases from osteoporosis to cancer. The business case is being driven by FDA requirements for imaging data as part of clinical trial submissions. Biomark will provide firms with individualized services and results. The company’s president is Dr Osama Sherif...